GRAIL (NASDAQ:GRAL) Releases Earnings Results, Beats Expectations By $0.47 EPS

GRAIL (NASDAQ:GRAL) issued its quarterly earnings data on Tuesday. The company reported ($2.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47, Zacks reports. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. The business had revenue of $40.79 million for the quarter, compared to analysts’ expectations of $39.16 million.

Here are the key takeaways from GRAIL’s conference call:

• GRAIL sold over 56,000 Galleri tests in Q1 (a 50% YoY increase) and reported screening revenue of $39.8M, citing expanding physician adoption and new health-system and employer partnerships.
• The FDA has accepted GRAIL’s PMA submission for review (PATHFINDER 2 and NHS-Galleri data plus a bridging analysis), but timing, the possibility of an advisory committee, and the ultimate outcome remain uncertain.
• The NHS-Galleri trial did not meet its combined primary endpoint (no significant reduction in combined stage 3+4), which could be viewed unfavorably by some stakeholders despite accompanying secondary benefits.
• Q1 non-GAAP results improved with adjusted gross profit of $19.7M, a narrower adjusted EBITDA loss (-$79.9M), a 12% smaller net loss, and cash of $823.1M to fund growth and milestones.
• Management reiterated 2026 revenue guidance (22–32%), plans a mid-year salesforce ramp and Epic/Quest/Athena integrations to ease provider ordering, but the pace of uptake from new digital and employer partners and ASP/mix effects are uncertain.

GRAIL Stock Performance

Shares of GRAIL stock traded up $4.85 during midday trading on Wednesday, reaching $59.25. 318,583 shares of the company’s stock traded hands, compared to its average volume of 1,115,104. The company has a market cap of $2.54 billion, a price-to-earnings ratio of -5.30 and a beta of 3.03. The company’s 50 day simple moving average is $50.40 and its 200 day simple moving average is $78.71. GRAIL has a 52 week low of $29.95 and a 52 week high of $118.84.

Insider Activity

In other news, CFO Aaron Freidin sold 45,806 shares of the stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the transaction, the chief financial officer owned 260,669 shares of the company’s stock, valued at approximately $13,012,596.48. This represents a 14.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Joshua J. Ofman sold 61,665 shares of the stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $3,078,316.80. Following the transaction, the president directly owned 371,216 shares in the company, valued at approximately $18,531,102.72. This represents a 14.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 310,267 shares of company stock worth $15,485,396.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC grew its position in GRAIL by 5.2% in the 4th quarter. Parallel Advisors LLC now owns 2,667 shares of the company’s stock worth $228,000 after purchasing an additional 133 shares during the last quarter. Comerica Bank raised its stake in shares of GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares during the last quarter. Rossby Financial LCC raised its stake in shares of GRAIL by 25.0% during the fourth quarter. Rossby Financial LCC now owns 1,250 shares of the company’s stock worth $107,000 after buying an additional 250 shares during the last quarter. Blair William & Co. IL raised its stake in shares of GRAIL by 5.3% during the third quarter. Blair William & Co. IL now owns 5,356 shares of the company’s stock worth $317,000 after buying an additional 268 shares during the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of GRAIL by 1.0% during the third quarter. Van ECK Associates Corp now owns 26,773 shares of the company’s stock worth $1,583,000 after buying an additional 268 shares during the last quarter.

Analyst Ratings Changes

Several research firms have recently issued reports on GRAL. Robert W. Baird set a $70.00 price objective on shares of GRAIL in a report on Wednesday. TD Cowen restated a “buy” rating on shares of GRAIL in a report on Wednesday. Morgan Stanley reduced their target price on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Tuesday, April 21st. Finally, Mizuho began coverage on shares of GRAIL in a report on Friday, April 10th. They set a “neutral” rating and a $58.00 target price for the company. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $67.38.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.